Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) shares traded down 3.3% during mid-day trading on Friday . The stock traded as low as $7.25 and last traded at $7.39. 127,919 shares traded hands during trading, a decline of 81% from the average session volume of 689,240 shares. The stock had previously closed at $7.64.
Wall Street Analyst Weigh In
Several research firms have weighed in on TNGX. HC Wainwright upped their price target on Tango Therapeutics from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. Piper Sandler assumed coverage on shares of Tango Therapeutics in a report on Monday, February 12th. They issued an "overweight" rating and a $18.00 price target on the stock. Wedbush reiterated an "outperform" rating and issued a $18.00 price target on shares of Tango Therapeutics in a research note on Monday, March 18th. Cantor Fitzgerald began coverage on shares of Tango Therapeutics in a report on Thursday. They set an "overweight" rating for the company. Finally, B. Riley initiated coverage on Tango Therapeutics in a report on Friday, December 8th. They issued a "buy" rating and a $16.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $17.25.
View Our Latest Analysis on Tango Therapeutics
Tango Therapeutics Price Performance
The company has a market cap of $787.59 million, a P/E ratio of -6.71 and a beta of 0.83. The firm's 50-day moving average is $10.41 and its two-hundred day moving average is $9.65.
Insiders Place Their Bets
In other Tango Therapeutics news, CEO Barbara Weber sold 4,681 shares of the business's stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total transaction of $58,793.36. Following the sale, the chief executive officer now directly owns 1,539,624 shares of the company's stock, valued at $19,337,677.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder Rock Ventures Iv L.P. Third sold 162,500 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $12.00, for a total value of $1,950,000.00. Following the sale, the insider now owns 19,201,475 shares of the company's stock, valued at $230,417,700. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Barbara Weber sold 4,681 shares of the firm's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $12.56, for a total transaction of $58,793.36. Following the completion of the sale, the chief executive officer now owns 1,539,624 shares of the company's stock, valued at approximately $19,337,677.44. The disclosure for this sale can be found here. Insiders sold 174,731 shares of company stock valued at $2,103,703 in the last three months. Corporate insiders own 6.20% of the company's stock.
Hedge Funds Weigh In On Tango Therapeutics
Several hedge funds have recently bought and sold shares of the business. Clear Harbor Asset Management LLC raised its position in Tango Therapeutics by 5.3% during the 4th quarter. Clear Harbor Asset Management LLC now owns 21,200 shares of the company's stock valued at $210,000 after purchasing an additional 1,069 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Tango Therapeutics by 11.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,345 shares of the company's stock valued at $113,000 after buying an additional 1,129 shares during the period. California State Teachers Retirement System raised its holdings in shares of Tango Therapeutics by 2.6% in the second quarter. California State Teachers Retirement System now owns 61,401 shares of the company's stock valued at $204,000 after acquiring an additional 1,536 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Tango Therapeutics by 0.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 369,066 shares of the company's stock worth $3,654,000 after acquiring an additional 1,709 shares during the period. Finally, American Century Companies Inc. grew its holdings in Tango Therapeutics by 8.3% during the 3rd quarter. American Century Companies Inc. now owns 23,718 shares of the company's stock worth $267,000 after acquiring an additional 1,826 shares in the last quarter. Institutional investors own 78.99% of the company's stock.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
